F
Fiona Lalloo
Researcher at University of Manchester
Publications - 212
Citations - 17366
Fiona Lalloo is an academic researcher from University of Manchester. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 56, co-authored 189 publications receiving 14907 citations. Previous affiliations of Fiona Lalloo include National Health Service & Imperial College London.
Papers
More filters
Journal ArticleDOI
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies
Antonis C. Antoniou,Paul D.P. Pharoah,Steven A. Narod,Harvey A. Risch,Jorunn E. Eyfjord,John L. Hopper,Niklas Loman,Håkan Olsson,Oskar T. Johannsson,Åke Borg,Barbara Pasini,Paolo Radice,Siranoush Manoukian,Diana Eccles,Nelson L.S. Tang,E. Olah,Hoda Anton-Culver,Ellen Warner,Jan Lubinski,Jacek Gronwald,Bohdan Górski,Hrafn Tulinius,Steinunn Thorlacius,Hannaleena Eerola,Heli Nevanlinna,Kirsi Syrjäkoski,Olli Kallioniemi,Deborah J. Thompson,Christopher H. Evans,Julian Peto,Julian Peto,Fiona Lalloo,D G R Evans,Douglas F. Easton +33 more
TL;DR: Risks in carriers were higher when based on index breast cancer cases diagnosed at <35 years of age and for variation in risk by mutation position for both genes, and some evidence for a reduction in risk in women from earlier birth cohorts is found.
Journal ArticleDOI
Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.
D G R Evans,E. Howard,E. Howard,C. Giblin,C. Giblin,Thomas E. Clancy,Thomas E. Clancy,H. Spencer,H. Spencer,Susan M Huson,Susan M Huson,Fiona Lalloo,Fiona Lalloo +12 more
TL;DR: Estimates for NF1, NF2, FAP, and VHL are in line with previous estimates, and the first estimates of birth incidence and de novo mutation rate for Gorlin syndrome are provided.
Journal ArticleDOI
Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype
Sunil R. Lakhani,Jorge S. Reis-Filho,L G Fulford,Frédérique Penault-Llorca,Marc van der Vijver,Suzanne Parry,Timothy Bishop,Javier Benitez,Rivas C,Yves-Jean Bignon,Jenny Chang-Claude,Ute Hamann,Cees J. Cornelisse,Peter Devilee,Matthias W. Beckmann,Carolin Nestle-Krämling,Peter A. Daly,Neva E. Haites,Jenny Varley,Fiona Lalloo,G Evans,Christine Maugard,Hanne Meijers-Heijboer,Jan G. M. Klijn,Edith Olah,Barry A. Gusterson,Silvana Pilotti,Paolo Radice,Siegfried Scherneck,Hagay Sobol,Jocelyne Jacquemier,Teresa Wagner,Julian Peto,Michael R. Stratton,Lesley McGuffog,Douglas F. Easton +35 more
TL;DR: The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCa1 mutation testing.
Journal ArticleDOI
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts
Hans F. A. Vasen,Ignacio Blanco,Katja Aktan-Collan,Jessica P. Gopie,Angel Alonso,Stefan Aretz,Inge Bernstein,Lucio Bertario,John Burn,Gabriel Capellá,Chrystelle Colas,Christoph Engel,Ian M. Frayling,Maurizio Genuardi,Karl Heinimann,Frederik J. Hes,Shirley Hodgson,John A. Karagiannis,Fiona Lalloo,Annika Lindblom,Jukka-Pekka Mecklin,Pål Møller,Torben Myrhøj,Fokko M. Nagengast,Yann Parc,Maurizio Ponz de Leon,Laura Renkonen-Sinisalo,Julian R. Sampson,Astrid Stormorken,Rolf H. Sijmons,Sabine Tejpar,Huw Thomas,Nils Rahner,Juul T. Wijnen,Heikki Järvinen,Gabriela Möslein +35 more
TL;DR: The guidelines described in this paper may be helpful for the appropriate management of families with LS and Prospective controlled studies should be undertaken to improve further the care of these families.
Journal ArticleDOI
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Chey Loveday,Clare Turnbull,Emma Ramsay,Deborah Hughes,Elise Ruark,Jessica Frankum,Georgina Bowden,Bolot Kalmyrzaev,Margaret Warren-Perry,Katie Snape,Julian Adlard,Julian Barwell,Jonathan Berg,Angela F. Brady,Carole Brewer,G Brice,C Chapman,Jackie Cook,Rosemarie Davidson,Alan Donaldson,Fiona Douglas,Lynn Greenhalgh,Alex Henderson,Louise Izatt,Ajith Kumar,Fiona Lalloo,Zosia Miedzybrodzka,Patrick J. Morrison,Joan Paterson,Mary Porteous,Mark T. Rogers,Susan Shanley,Lisa Walker,Diana Eccles,D. Gareth Evans,Anthony Renwick,Sheila Seal,Christopher J. Lord,Alan Ashworth,Jorge S. Reis-Filho,Antonis C. Antoniou,Nazneen Rahman +41 more
TL;DR: It is shown that cells deficient in RAD51D are sensitive to treatment with a PARP inhibitor, suggesting a possible therapeutic approach for cancers arising in RAD 51D mutation carriers.